In this paper, we have demonstrated that, in both AML subtypes, high ALDH activity is an unique marker distinguishing CD34+CD38– HSC from CD34+ and CD34– LSC present within the BM of all the AML cases studied. This evidence concerns the gene CD34 and acute myeloid leukemia.